Applications to the adMare Executive Institute’s 2020-2021 session are now being accepted until June 30, 2020.
The keystone principle in planning for our future is clear: while security of domestic supply is important, security of domestic knowledge is critical.
Working in partnership with adMare, Variational AI will apply generative artificial intelligence to identify already-approved medications that can be expeditiously repurposed to fast-track life-saving treatment for COVID-19 patients.
The proceeds from the financing will fund Phase 1 & Phase 2 clinical trials of ZT-01, Zucara’s first-in-class drug candidate designed to prevent hypoglycemia in Type 1 Diabetes (T1D), a frequent, unintended consequence of insulin therapy for people with T1D & other types of insulin-dependent diabetes.
adMare BioInnovations & BELLUS have closed an agreement under which BELLUS has acquired full ownership of intellectual property previously licensed from adMare. BELLUS will own 100% of the BLU-5937 assets, and adMare’s remaining rights have been fully converted into equity in the company.
adMare BioInnovations Portfolio Company SoundBite Receives FDA 510(k) Clearance of the SoundBite™ Crossing System – Peripheral MONTREAL – SoundBite Medical Solutions Inc. (SBMS)today announces it has received U.S. Food and…
The addition of Accel-Rx’s expertise in seed stage investments and entrepreneur development strengthens adMare’s position as a single-stop destination with the necessary scientific, business, infrastructure, and capital resources to grow and scale health related technology companies in Canada.
With deep experience in corporate and business development, Dr. Azzi will work closely with adMare’s Venture Partners to build their portfolios through new program creation and advance adMare’s Mission to source therapeutically and commercially promising research from leading academic and biotech partners from across Canada to create and grow companies of scale.